It has not been an easy road but Lexicon, a biopharmaceutical company, has received FDA approval for Inpefa (sotagliflozin), a treatment to reduce the risk of heart failure for patients with Type 2 diabetes chronic kidney disease, and other cardiovascular risk factors. The once-daily pill is due to become available by the end of June.
Click here to read the entire article.